The upcoming FDA catalyst everyone is sleeping on (Remember ABVX)

{"summary": "Author argues Medincell's once-monthly olanzapine injection addresses a multi-billion dollar market with high-margin royalties and zero commercial burn, with a potential +200% move on FDA approval.", "reason": "The author provides a fundamental rationale (addressable market size and royalty model) and a specific catalyst (FDA approval) for a long position.", "ideas": [{"symbol": "MEDCL.PA", "direction": "long", "thesis": "The author claims 20-30% of oral olanzapine patients are immediate candidates for a safe once-monthly injection, creating a multi-billion dollar addressable market where Medincell captures high-margin royalty streams with zero commercial burn. The catalyst is FDA approval, which the author says would send the stock up over 200% instantly and validate their BEPO platform. The main risk implied is binary FDA decision risk, though not explicitly framed as a risk.", "thesis_short": "Medincell FDA approval could trigger +200% move", "quote": "If the FDA gives the green light, this well go +200% instantly. It validates their unique BEPO platform", "confidence": 0.65, "sentiment": 0.8, "timeframe": "unspecified"}], "model": "gemini-3.1-flash-lite", "failure_count": 0, "verified": true, "extraction_model": "deepseek-flash"}